

codes are required in 37 CFR is at 3.21, which refers to assignments. An application is not an assignment.

Points 4 and 5 do not require a response.

Turning to point 6A, the rejection is very unclear. "Of matter" has been deleted from the claim, as this is clear, but the rest of the rejection is baffling. Essentially, 6A depends from 6B in the rejection, because it seems that the Examiner has an issue with the term "isolated". "Isolated" as used in these claims refers to the tumor rejection antigen precursor *per se*. This should address the rejection. If it does not, then a clearer exposition of the issues would be appreciated.

Regarding the rejection at 6C, this is unclear, since "tumor rejection antigen" is not used in the claims. Rather, tumor rejection antigen precursor is what is used. This is defined in the specification. Please see the discussion starting at page 4, line 18, extending through page 6, line 26, especially page 6, lines 18-26. The term is well defined. Claim 175 has been amended to refer to SEQ ID NO: 8. The rest of the questions in rejection 6C are not understood.

As for rejection 6D, "tum-" is amended to -- tum⁻ --.

Turning to rejection 7, the Examiner states that claim 176 does not further limit claimed subject matter. Apparently, the Examiner interprets claim 176 as being drawn to MAGE-1.


Claim 176 is not drawn to MAGE-1. The claim is drawn to tumor rejection antigen precursors whose encoding DNA hybridizes to the DNA encoding MAGE-1. All of MAGE-1 through MAGE-12, *e.g.*, satisfy this claim. There is no basis for concluding that claim 176 is drawn to MAGE-1.

As to rejection 8, the Examiner states that claim 181 does not further limit the claims. It does. It is well known that not all pharmaceutically appropriate ingredients are also appropriate as vaccines. Conversely, all vaccines must be pharmaceutically appropriate ingredients.

All issues raised have been addressed. Allowance of this application is believed proper, and is urged.

Respectfully submitted,

FELFE & LYNCH



Norman D. Hanson
Reg. No. 30,946

805 Third Avenue
New York, NY 10022
(212) 688-9200